COMP <GO>
ADRX vs ZBIO // NET PROFIT MARGIN
ADARx Pharmaceuticals Inc. (NASDAQ) VS. Zenas BioPharma Inc. (NASDAQ) • 15-METRIC TALLY: ADRX 1
— ZBIO 1
■ METRIC PARITY
LAST: $17.85 (-0.56%) • MKT CAP: $1.91B
net-margins
—
LAST: $28.76 (-0.04%) • MKT CAP: $1.87B
net-margins
-60.00%
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (ADRX VS. ZBIO)
EMERALD CELL = QUANTITATIVE EDGE
| INSTITUTIONAL METRIC | ADRX | ZBIO | SPREAD (A - B) | ADVANTAGE | DEDICATED URL |
|---|---|---|---|---|---|
| Gross Profit Margin | — | — | — | TIE | /gross-margins <GO> |
| Return on Invested Capital (ROIC) | — | -35.00% | — | TIE | /roic <GO> |
| EV/EBITDA & P/E Valuation | — | — | — | TIE | /valuation <GO> |
| Free Cash Flow Yield | — | -9.19% | — | TIE | /fcf-yield <GO> |
| Operating Margin | — | -60.00% | — | TIE | /operating-margins <GO> |
| Net Profit Margin ACTIVE | — | -60.00% | — | TIE | /net-margins <GO> |
| Revenue Growth (YoY) | — | 100.00% | — | TIE | /revenue-growth <GO> |
| Dividend Yield & FCF Payout Safety | 0.00% | 0.00% | 0.00 | TIE | /dividend-safety <GO> |
| Altman Z-Score & Debt/Equity | — | 2.79 | — | TIE | /balance-sheet <GO> |
| Piotroski F-Score Quality | — | 4/9 | — | TIE | /piotroski-score <GO> |
| Options Implied Move & Put/Call Skew | — | — | — | TIE | /options-implied-move <GO> |
| RSI-14 & 200D SMA Momentum | 36.8 | 52.3 | -15.48 | ZBIO | /rsi-technicals <GO> |
| 10Y Yield & FRED Macro Beta | — | — | — | TIE | /macro-sensitivity <GO> |
| Forward P/E Multiple | — | — | — | TIE | /forward-pe <GO> |
| Enterprise Scale & Market Cap | $1.91B | $1.87B | $31.9M | ADRX | /market-cap <GO> |
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
| FISCAL YEAR | ADRX REV | ZBIO REV | ADRX GROSS % | ZBIO GROSS % | ADRX FCF | ZBIO FCF |
|---|---|---|---|---|---|---|
| FY 2025 | — | $10.0M | — | — | — | -$172.4M |
| FY 2024 | — | $5.0M | — | — | — | -$119.8M |
| FY 2023 | — | $50.0M | — | — | — | -$30.5M |
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
ADRX // BETA —
ZBIO // BETA —